GNRH-A Triptorelin

Small molecule

LLebanese University

GNRH-A Triptorelin is one of 19 small molecule programs targeting Female Infertility. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Female InfertilityActive, not recruiting

Female InfertilityPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Female Infertility

#DrugCompanyPhaseTrials

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—2

Gynorest

SSolvay Pharmaceuticals

Approved

—3

Viagra

VViatris Specialty LLC

Prometrium

Clomid

Orgalutran

Human Chorionic Gonadotropin

Merck & Co.

Phase 2

1 8

Gnrh Ant

Merck & Co.

Phase 2

1 9

Homoeopathic Medicines

FFr Muller Homoeopathic Medical College

Phase 3

1 10

Genotropin

EMD Serono

Phase 1

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Female Infertility1 trial

Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

Completed·LLebanese University·Phase 1/2·NCT04071574·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GNRH-A Triptorelin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNRH-A Triptorelin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNRH-A Triptorelin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Lebanese University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: LLebanese University

GNRH-A Triptorelin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Female Infertility1 trial

References

Drug Info

Quick Facts

Related News